Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Interest & Investment Income (2021 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Interest & Investment Income for 9 consecutive years, with $230668.0 as the latest value for Q1 2026.

  • Quarterly Interest & Investment Income fell 9.79% to $230668.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $884723.0 through Jan 2026, down 54.23% year-over-year, with the annual reading at $1.4 million for FY2025, 58.35% down from the prior year.
  • Interest & Investment Income for Q1 2026 was $230668.0 at PharmaCyte Biotech, up from $206387.0 in the prior quarter.
  • The five-year high for Interest & Investment Income was $894181.0 in Q4 2023, with the low at $45459.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $443456.1, with a median of $382562.0 recorded in 2024.
  • The sharpest move saw Interest & Investment Income skyrocketed 1614.24% in 2022, then plummeted 71.0% in 2025.
  • Over 5 years, Interest & Investment Income stood at $439171.0 in 2022, then skyrocketed by 103.61% to $894181.0 in 2023, then crashed by 57.22% to $382562.0 in 2024, then tumbled by 46.05% to $206387.0 in 2025, then grew by 11.76% to $230668.0 in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $230668.0, $206387.0, and $217793.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.